Bioxytran Partners with University of Minnesota to Advance Carbohydrate-Based Therapeutics Through NMR Research
Key Insights
Bioxytran (search) has executed a sponsored research agreement with the University of Minnesota to advance understanding of polysaccharide and oligosaccharide interactions with biological targets.
The collaboration will utilize advanced nuclear magnetic resonance spectroscopy under Dr. Kevin Mayo's direction to analyze carbohydrate-binding interactions and structural conformations.
The research program runs through early 2027 and aims to strengthen the scientific foundation for Bioxytran (search)'s carbohydrate-based technology platform spanning glycovirology (search), hypoxia (search), and degenerative diseases (search).
Clinical-stage biotechnology company Bioxytran (search) has announced a sponsored research agreement with the University of Minnesota to advance the development of novel carbohydrate-based therapeutics through sophisticated molecular analysis techniques. The collaboration aims to deepen understanding of how polysaccharides (search) and oligosaccharides (search) interact with biologically relevant targets, potentially unlocking new therapeutic pathways.
Research Program Structure
The research will be conducted under the direction of Dr. Kevin Mayo, a recognized expert in biomolecular structure and nuclear magnetic resonance spectroscopy at the University of Minnesota. The program will utilize state-of-the-art nuclear magnetic resonance methodologies to analyze binding interactions, structural conformations, and affinity characteristics of select carbohydrate compounds (search).
"This collaboration with the University of Minnesota represents an important step in strengthening the scientific foundation behind our carbohydrate-based technology platform," said David Platt, CEO of Bioxytran (search). "By leveraging the University's deep expertise in structural biology and advanced nuclear magnetic resonance spectroscopy, we aim to generate high-quality data that supports the continued evolution of our research and development pipeline."
Scientific Focus and Applications
The sponsored research program will explore how specific polysaccharides (search) and related carbohydrate structures interact with target molecules relevant to biological systems. The work is expected to build on Bioxytran (search)'s existing research into carbohydrate-based materials and their potential applications across biomedical and life-science domains.
The collaboration is designed to further characterize carbohydrate-binding interactions that may play a role in future therapeutic and diagnostic applications. Findings from the study may help guide future development strategies and inform additional preclinical research initiatives.
Partnership Framework
The research term is expected to run through early 2027, with defined milestones, periodic progress reviews, and structured reporting. Bioxytran (search) will provide funding to support research personnel, nuclear magnetic resonance facility access, and associated laboratory resources required to execute the program.
In accordance with standard sponsored research practices, the University of Minnesota will retain ownership of any intellectual property generated through the research, while Bioxytran (search) will receive broad rights to use the resulting research data for internal research and development purposes.
"This type of partnership exemplifies how academic research institutions and innovative companies can work together to address complex scientific questions," said Dr. Kevin Mayo, Principal Investigator and Professor at the University of Minnesota. "Our goal is to apply advanced analytical tools to generate insights that are both scientifically meaningful and relevant to real-world applications."
Strategic Implications
For Bioxytran (search), the collaboration supports a broader strategy focused on strengthening scientific validation, expanding academic partnerships, and advancing next-generation carbohydrate technologies. The company believes that well-characterized molecular interactions are a critical step toward unlocking new therapeutic pathways and accelerating innovation.
The agreement reflects a shared commitment to advancing scientific knowledge through collaboration between academia and industry, with the University of Minnesota carrying out the research in accordance with its established academic standards, ensuring scientific rigor, transparency, and adherence to institutional research policies.